IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection.
- Mohammed Eslam
- , Reynold Leung
- , Manuel Romero-Gomez
- , Alessandra Mangia
- , William L. Irving
- , David Sheridan
- , Ulrich Spengler
- , Lindsay Mollison
- , Wendy Cheng
- , Elisabetta Bugianesi
- , Duncan McLeod
- , Abed M. Zaitoun
- , Vito Attino
- , Diane Goeltz
- , Jacob Nattermann
- , Mark Douglas
- , David R. Booth
- , Jacob George*
- , Golo Ahlenstiel
*Corresponding author for this work
- University of Sydney
- Hospital Universitario de Valme
- IRCCS Ospedale Casa Sollievo della Sofferenza - San Giovanni Rotondo (FG)
- University of Nottingham
- Newcastle University
- University of Bonn
- Fremantle Hepatitis Services
- Royal Perth Hospital
- Azienda Sanitaria Ospedaliera Molinette San Giovanni Battista Di Torino
- Westmead Hospital
- Nottingham University Hospitals NHS Trust
Research output: Contribution to journal › Article › peer-review